Browsing by Author "Öksüzoğlu, Berna"
Now showing items 1-10 of 10
-
The clinical and pathologic characteristics of 400 gastrointestinal stroinal tumor patients from Turkey: The final results of the Turkish Anatolian Society of Medical Oncology Multicenter Registery
Sevinç, Alper; Şeker, Mesut; Yıldız, Ramazan; Cihan, Şener; Kaplan, Mehmet Ali; Dane, Faysal; Karaca, Halit; Üyetürk, Ümmügül; Bilici, Ahmet; Özdemir, Nuriye; Uncu, Doğan; Salepçi, Tafian; Işıkdoğan, Abdurrahman; Benekli, Mustafa; Özkan, Metin; Gümüş, Mahmut; Öksüzoğlu, Berna (American Society of Clinical Oncology, 2014)… -
Economic burden of gastric cancer in Turkey
Bilici, Ahmet; Gümüş, Mesut; Malhan, Simten; Öksüz, Emine; Öksüzoğlu, Berna; Yalçın, Serhat (Elsevier Science Inc, 2017)Human papillomavirus (HPV) infection is a pre-requisite for vaginal and vulval cancers. The incidence of vaginal cancer in the UK has remained relatively stable over the past 25 years; however the age-standardised incidence ... -
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group
Erol, Cihan; Şendur, Mehmet Ali Nahit; Bilgetekin, İrem; Bayır Garbioğlu, Duygu; Hamdard, Jamshid; Akbaş, Sinem; Hizal, Mutlu; Arslan, Çağatay; Sevinç, Alper; Küçükarda, Ahmet; Erdem, Dilek; Kahraman, Seda; Çakır, Emre; Demirkıran, Aykut; On, Sercan; Doğan, İzzet; Erdoğan, Atike Pınar; Koca, Sinan; Kubilay, Pınar; Eren, Orhan Önder; Çılbır, Ebru; Çelik, Emir; Araz, Murat; Tataroğlu Özyükseler, Deniz; Yıldırım, Mahmut Emre; Bahçeci, Aykut; Taşkaynatan, Halil; Oyman, Abdilkerim; Deniz, Gülhan İpek; Menekşe, Serkan; Kut, Engin; Gülmez, Ahmet; Sakin, Abdullah; Nayır, Erdinç; Acar, Ramazan; Şen, Erdem; İnal, Ali; Turhal, Serdar; Kaya, Ali Osman; Paydaş, Semra; Taştekin, Didem; Hacıbekiroğlu, İlhan; Çinçin, İrfan; Bilici, Ahmet; Mandel, Nil Molinas; Şener Dede, Didem; Akıncı, Muhammed Bülent; Öksüzoğlu, Berna; Uncu, Doğan; Yalçın, Bülent; Artaç, Mehmet (NLM (Medline), 2022)Aims: The addition of aflibercept to the fluorouracil and irinotecan (FOLFIRI) regimen significantly improved clinical outcomes in patients with metastatic colorectal cancer (CRC) previously treated with oxaliplatin. We ... -
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
Karacin, Cengiz; Öksüzoğlu, Berna; Demirci, Ayşe; Keskinkılıç, Merve; Baytemür, Naziyet Köse; Yılmaz, Funda; Selvi, Oğuzhan; Erdem, Dilek; Avşar, Esin; Paksoy, Nail; Demir, Necla; Göksu, Sema Sezgin; Türker, Sema; Bayram, Ertuğrul; Çelebi, Abdüssamet; Yılmaz, Hatice; Kuzu, Ömer Faruk; Kahraman, Seda; Gökmen, İvo; Sakin, Abdullah (BioMed Central Ltd, 2023)Background: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which ... -
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (vol 23, 136, 2023)
Karacin, Cengiz; Öksüzoğlu, Berna; Demirci, Ayşe; Keskinkılıç, Merve; Köse Baytemur, Naziyet; Yılmaz, Funda; Selvi, Oğuzhan; Hacıbekiroğlu, İlhan (BMC, 2023)Following publication of the original article [1], the authors reported an error in the author name of Enes Erul. -
Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study)
Bilici, Ahmet; Ölmez, Ömer Fatih; Sezer, Ahmet; Öksüzoğlu, Berna; Kaplan, Muhammet Ali; Karadurmuş, Nuri; Çubukçu, Erdem; Şendur, Mehmet Ali Nahit; Aksoy, Sercan; Erdem, Dilek; Başaran, Gül; Çakar, Burcu; Şeker, Mesut; Arslan, Çağatay; Sezgin Göksu, Sema; Çiçin, İrfan; Gümüş, Mahmut; Selçukbiricik, Fatih; Harputluoğlu, Hakan; Helvacı, Kaan (Lippincott Williams and Wilkins, 2022)... -
The real-life efficacy of the second line treatment strategy in advanced pancreas cancer
Hızal, Mutlu; Şendur, Mehmet Ali Nahit; Bilgin, Burak; Karcı Güner, Ebru; Akıncı, Muhammed Bülent; Ergün, Yakup; Esin, Ece; Köksoy, Elif Berna; Sezer, Ahmet; Özdemir, Nuriye; Öksüzoğlu, Berna; Yalçın, Bülent; Utkan, Güngör; Ürün, Yüksel (Turkiye Klinikleri, 2022)ABS TRACT Objective: Pancreatic cancer is one of the leading causes of cancer-related death. Despite the introduction of new therapeutic agents, survival rates remain low. Furthermore, few trials have evaluated the options ... -
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: A Turkish Oncology Group study
Hızal, Mutlu; Bilgin, Burak; Paksoy, Nail; Kılıçkap, Sadettin; Atcı, Muhammed Mustafa; Kahraman, Seda; Keskinkılıç, Merve; Bilgetekin, İrem; Ayhan, Murat; Tural, Deniz; Eren, Önder; Akkoç Mustafayev, Fatma Nihan; Yaman, Şebnem; Tatlı, Ali Murat; Bayram, Ertuğrul; Kutlu, Yasin; Ertürk, İsmail; Özcan, Erkan; Gülmez, Ahmet; Korkmaz, Mustafa; Akagündüz, Baran; Erdem, Dilek; Akın Telli, Tuğba; Aksoy, Asude; Üskent, Necdet; İriağaç, Yakup; Köse Baytemür, Naziyet; Aydın, Dinçer; Sakalar, Teoman; Arak, Haci; Selçukbiricik, Fatih; Ergün, Yakup; Korkmaz, Taner; Ak, Naziye; Ünal, Çağlar; Akdeniz, Nadiye; Özgün, Mehmet Alpaslan; Öksüzoğlu, Berna; Yalçın, Bülent; Öztop, İlhan; Algın, Efnan; Sakin, Abdullah; Aydıner, Adnan; Yumuk, Perran Fulden; Şendur, Mehmet Ali Nahit (Future Medicine Ltd., 2022)Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell ... -
Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases
Ulaş, Arife; Bilici, Ahmet; Durnalı, Ayşe; Tokluoğlu, Saadet; Akıncı, Sema; Silay, Kamile; Öksüzoğlu, Berna; Alkış, Necati (Sage Publications Ltd, 2016)Skeletal-related events (SREs) for nonsmall cell lung cancer (NSCLC) patients with bone metastasis lead to serious morbidity. The aim of this study was to determine risk factors for SREs in NSCLC patients with bone metastasis ...
